Paper Details
- Home
- Paper Details
Original Abstract of the Article :
This introduction provides an overview of the succeeding articles contained within this supplement on the new fourth-generation fluoroquinolone antibiotic product, moxifloxacin ophthalmic solution 0.5% (VIGAMOX, Alcon Laboratories, Inc., Fort Worth, TX). Moxifloxacin was developed specifically to ad...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/j.survophthal.2005.05.001
データ提供：米国国立医学図書館（NLM）
Moxifloxacin: A New Frontier in Ophthalmic Anti-Infective Therapy
This study dives into the critical world of ophthalmic infections and their ever-evolving treatment landscape. It introduces moxifloxacin, a fourth-generation fluoroquinolone antibiotic, as a potent weapon against a wide array of bacteria. The study examines the efficacy and safety of moxifloxacin ophthalmic solution 0.5% in various scenarios, including surgical prophylaxis and treatment of sight-threatening infections such as conjunctivitis, endophthalmitis, and keratitis.
Moxifloxacin’s Advantage: Combating Resistance
The researchers highlight the increasing prevalence of resistance to older antibiotic molecules, underscoring the need for newer, more effective agents like moxifloxacin. Moxifloxacin has been shown to exhibit superior activity compared to previous generations, boasting exceptional potency against both gram-positive and gram-negative organisms, including atypical mycobacteria. The study emphasizes the unique molecular structure of moxifloxacin, which enables enhanced corneal penetration and bioavailability, further amplifying its effectiveness.
Hope for the Future of Ophthalmic Infections
This research provides a beacon of hope for patients struggling with ophthalmic infections. Moxifloxacin’s broad spectrum of activity and favorable safety profile present a promising solution for combating infections, particularly those that have become resistant to conventional treatments. This study showcases the dynamism of the field of ophthalmology, as new generations of antibiotics continue to emerge, offering hope for a brighter future in the fight against infections.
Dr.Camel's Conclusion
The relentless march of bacterial resistance is like a desert storm, threatening to engulf our efforts to treat infections. Moxifloxacin, with its advanced molecular structure and broad spectrum of activity, stands as a sturdy oasis in this arid landscape, offering a much-needed respite in the fight against ophthalmic infections.
Date :
- Date Completed 2006-01-03
- Date Revised 2018-12-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.